Literature DB >> 26355082

Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.

Young-Chan Kwon1, Sandip K Bose2, Robert Steele3, Keith Meyer1, Adrian M Di Bisceglie2, Ratna B Ray3, Ranjit Ray4.   

Abstract

UNLABELLED: We have previously reported that hepatitis C virus (HCV) infection of primary human hepatocytes (PHH) induces the epithelial mesenchymal transition (EMT) state and extends hepatocyte life span (S. K. Bose, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray, J Virol 86:13621-13628, 2012, http://dx.doi.org/10.1128/JVI.02016-12). These hepatocytes displayed sphere formation on ultralow binding plates and survived for more than 12 weeks. The sphere-forming hepatocytes expressed a number of cancer stem-like cell (CSC) markers, including high levels of the stem cell factor receptor c-Kit. The c-Kit receptor is regarded as one of the CSC markers in hepatocellular carcinoma (HCC). Analysis of c-Kit mRNA displayed a significant increase in the liver biopsy specimens of chronically HCV-infected patients. We also found c-Kit is highly expressed in transformed human hepatocytes (THH) infected in vitro with cell culture-grown HCV genotype 2a. Further studies suggested that HCV core protein significantly upregulates c-Kit expression at the transcriptional level. HCV infection of THH led to a significant increase in the number of spheres displayed on ultralow binding plates and in enhanced EMT and CSC markers and tumor growth in immunodeficient mice. The use of imatinib or dasatinib as a c-Kit inhibitor reduced the level of sphere-forming cells in culture. The sphere-forming cells were sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment. Further, stattic, an inhibitor of the Stat3 molecule, induced sphere-forming cell death. A combination of sorafenib and stattic had a significantly stronger effect, leading to cell death. These results suggested that HCV infection potentiates CSC generation, and selected drugs can be targeted to efficiently inhibit cell growth. IMPORTANCE: HCV infection may develop into HCC as an end-stage liver disease. We focused on understanding the mechanism for the risk of HCC from chronic HCV infection and identified targets for treatment. HCV-infected primary and transformed human hepatocytes (PHH or THH) generated CSC. HCV-induced spheres were highly sensitive to cell death from sorafenib and stattic treatment. Thus, our study is highly significant for HCV-associated HCC, with the potential for developing a target-specific strategy for improved therapies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355082      PMCID: PMC4645669          DOI: 10.1128/JVI.01946-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  Signal transduction via the stem cell factor receptor/c-Kit.

Authors:  L Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

2.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

Review 3.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.

Authors:  Vera Levina; Adele Marrangoni; Tingting Wang; Simul Parikh; Yunyun Su; Ronald Herberman; Anna Lokshin; Elieser Gorelik
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

6.  GATA2 and Sp1 positively regulate the c-kit promoter in mast cells.

Authors:  Keiko Maeda; Chiharu Nishiyama; Hideoki Ogawa; Ko Okumura
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

Review 7.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Authors:  Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

8.  Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.

Authors:  H Quan; F Zhou; D Nie; Q Chen; X Cai; X Shan; Z Zhou; K Chen; A Huang; S Li; N Tang
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

9.  Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes.

Authors:  Arnab Basu; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

10.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

View more
  24 in total

1.  Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.

Authors:  Mustafa Nazzal; Subhayan Sur; Robert Steele; Mousumi Khatun; Tapas Patra; Nancy Phillips; John Long; Ranjit Ray; Ratna B Ray
Journal:  Hepatology       Date:  2020-08       Impact factor: 17.425

2.  Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Authors:  Young-Chan Kwon; Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

3.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

4.  Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model.

Authors:  Reina Sasaki; Pradip Devhare; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

5.  SULF1/SULF2 reactivation during liver damage and tumour growth.

Authors:  Kurtis Graham; Joshua I Murphy; Gurtej K Dhoot
Journal:  Histochem Cell Biol       Date:  2016-03-25       Impact factor: 4.304

6.  Hepatitis C Virus Core Protein Modulates Endoglin (CD105) Signaling Pathway for Liver Pathogenesis.

Authors:  Young-Chan Kwon; Reina Sasaki; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

7.  Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.

Authors:  Da-Eun Nam; Angelina Angelucci; Dahsom Choi; Arnold Leigh; Hae Chang Seong; Young S Hahn
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

Review 8.  APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases.

Authors:  Charles B Nguyen; Courtney W Houchen; Naushad Ali
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 9.  Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship.

Authors:  Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-02       Impact factor: 17.425

Review 10.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.